Financhill
Back

Emergent BioSolutions Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Sell
39

EBS
Emergent BioSolutions

Last Price:
9.19
Seasonality Move:
6.33%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Emergent BioSolutions Price Quote

$9.19
+0.23 (+2.57%)
(Updated: November 6, 2024 at 5:55 PM ET)

Emergent BioSolutions Key Stats

Sell
39
Emergent BioSolutions (EBS) is a Sell

Day range:
$8.68 - $9.05
52-week range:
$1.42 - $15.10
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.44
P/B ratio:
1.23%

Volume:
848.5K
Avg. volume:
1.7M
1-year change:
270.25%
Market cap:
$474M
Revenue:
$1B
EPS:
$-11.24

How Much Does Emergent BioSolutions Make?

Is Emergent BioSolutions Growing As A Company?

  • What Is Emergent BioSolutions's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.25%
  • What Is Emergent BioSolutions's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Emergent BioSolutions Stock Price Performance

What Is Emergent BioSolutions 52-Week High & Low?

Emergent BioSolutions Price To Free Cash Flow

Is It Risky To Buy Emergent BioSolutions?

Is Emergent BioSolutions Cash Flow Positive?

  • What Is EBS Cash Flow From Operations?
    Cash flow from operations (TTM) is $77M
  • What Is Emergent BioSolutions’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$48.5M
  • What Is Emergent BioSolutions’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$45.7M

Emergent BioSolutions Return On Invested Capital

  • Is Management Doing A Good Job?
    EBS return on invested capital is -37.89%
  • What Is Emergent BioSolutions Return On Assets?
    ROA measures how assets are converting to revenues and is -31.86%
  • What Is EBS Return On Equity?
    ROE is a measure of profitability and is -87.53%

Emergent BioSolutions Earnings Date & Stock Price

Emergent BioSolutions Competitors

Emergent BioSolutions Dividend Yield

Emergent BioSolutions Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: -25.11% 34.05%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 8.00
Downside from Last Price: -10.71%

Major Shareholders

  • How many EBS shares are owned by institutional investors?
    42.8M EBS shares are owned by institutional investors
  • How many EBS shares are owned by insiders?
    3.9M EBS shares are owned by insiders